慢性阻塞性肺疾病急性加重期病原菌检出情况与病情评估被引量：17

导出

摘要目的研究慢性阻塞性肺疾病(COPD)急性加重期病原菌的分布、耐药情况与患者临床肺功能损伤情况、BODE积分之间的关系。方法对2005年3月～9月我院慢性阻塞性肺疾病急性加重的患者108例合格痰标本进行细菌和真菌培养,对细菌培养阳性者作菌落鉴别和以K-B琼脂扩散法检测药物敏感性。所有患者均行肺功能检查并进行BODE指数评测。结果108例患者的痰标本共分离出致病菌184株,其中G-菌117株(63.6%);G+菌38株(20.7%);真菌29株(15.8%)。G-菌主要以铜绿假单胞菌为主(42株),该类细菌对酶抑制剂复方制剂、四代头孢、碳青酶烯类敏感。极重度COPD患者G-菌、真菌的检出率明显高于中重度COPD患者;BODE积分越高的患者G-菌和真菌的检出率也越高。结论慢性阻塞性肺疾病急性加重期呼吸道感染仍以G-菌为主,其中以铜绿假单胞菌、大肠杆菌、克雷伯杆菌、不动杆菌最多见,酶抑制剂复方制剂及碳青酶烯类是治疗该类细菌的有效抗生素。G-菌(铜绿假单胞菌)和真菌可能是肺功能差、病情危重患者的优势菌。

作者杨艳娟程德云李熙霞方洵聂英

机构地区四川大学华西医院四川大学华西医院呼吸内科

出处《四川大学学报（医学版）》 CAS CSCD 北大核心 2007年第4期742-744,共3页 Journal of Sichuan University(Medical Sciences)

关键词慢性阻塞性肺疾病病原菌肺功能 BODE积分

分类号 R563.9 [医药卫生—呼吸系统] R446.5 [医药卫生—诊断学]

引文网络
相关文献

参考文献13

1马睿.COPD的基因易感性[J].国外医学（呼吸系统分册）,2003,23(1):1-4. 被引量：8
2Sethi S.Infectious etiology of acute exacebation of chronic bronchitis.Chest,2000;117(5 Suppl12):380s-385s.
3姚婉贞.慢性阻塞性肺疾病的急性加重[J].中华全科医师杂志,2004,3(4):223-224. 被引量：16
4慢性阻塞性肺疾病诊治指南[J].中华结核和呼吸杂志,2002,25(8):453-460. 被引量：5092
5Celli BR,NacNee W,AT S/ERS Task Force.Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004;23(4):932-946.
6Annie F,Bemadette G,Philippe HL,et al.Performance standards for antimicrobial susceptibility testing.National Committe for Clinical Laboratory Standard,2004;24(1):104-109.
7Bartolome R,Claudia G,Jose M,et al.The body-mass index,airflow obstruction,dyspnea,and exercise capacity index in chronic obstructive pulmonary disease.The New England Journal of Medicine,2004;350(10):1005-1012.
8王化芬,王晓军,吴敬霞.下呼吸道感染病原菌及其耐药性分析[J].实用医药杂志,2005,22(2):119-120. 被引量：3
9党斌温,张杰,唐明忠.下呼吸道感染者痰检出耐亚胺培南铜绿假单孢菌的流行状况[J].国外医学（呼吸系统分册）,2005,25(6):401-403. 被引量：1
10何静玲.1000例呼吸道感染病原菌结果分析[J].医师进修杂志,2005,28(2):45-46. 被引量：19

二级参考文献20

1Cardenosa-Cendrero JA, Sole-Violan J, Bordes-Benitez A, et al. Role of different routines of tracheal colonization in the development of pneumonia in patients receiving mechanical ventilation.Chest,1999,116:462
2Hanberger H, Garcia-Rodriguez JA,Gobernado M,et al. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European country. JAMA, 1999,281:67
3Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.Clin Infect Dis,2003,37(6) :745-51.
4Chamot E,Boffi EI,Amari E,et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.Antimicrob Agents Chemother,2003,47(9) :2756-2764.
5Hammerschlag MR,Chirgwin K,Roblin PM,et al.Persistent infection with chlamydia pneumonia following acute respiratory illness[J].Clin Infect Dis,1992,14(1):178-182.
6Grayston JT,Campbell LA,Kuo CC,et al.A new respiratory tract pathogen:chlamydia pneumoniae strain TWAR[J].J Infect DiS,1990,161(4):618.
7Von Hertzen L,Alakarppa H,Koskinen R,et al.Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease[J].Epidemiol Infct,1997,118(2):155-164.
8Mogulkoc N,Karakurt S,Isalska B,et al.Acute purulent exacerbation of chronic obstructive pulmonary disease and chlamydia pneumonia infection[J].Am J Respir Crit Care Med,1999,160(1):349-353.
9Cunningham AF,Johnston SL,Julious SA,et al.Chronic chlamydia pneumonia infection and asthma exacerbations in children[J].Eur Respir J,1998,11(2):345-349.
10Heinemann M,Susa M,Simmache U,et al.Growth of chlamydia pneumonia induces cytokine production and expression of CD14 in a human monocytic cell line[J].Infect Immun,1996,64(11):4 872-4 875.